id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-338968-b1gg2ha7	La Rosée, Felicitas	Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies	2020-08-20		.txt	text/plain	1087	55	36	COVID-19 is a pandemic illness forcing clinicians and clinician scientists to respond to an unforeseen 20% rate of hospital admissions due to respiratory distress and a sepsis-like hyperinflammatory cytokine release syndrome that develops in a subgroup of SARS-CoV2-infected patients. Initial results of the WUHAN COVID-19 cohort suggested a major impact of hyperinflammation characterized by a specific cytokine profile including IL-1β, IL-6, and TNF-α on patient outcome. The antiviral drug remdesivir (rem) applied at early stages and the corticosteroid dexamethasone (dex) in oxygen-dependent and severely affected patients by now seem the only disease-modifying agents with signals of efficacy in randomized controlled trials [1] . The reported patients worsened clinically despite active immunosuppression, but responded to rux, a JAK1/2 inhibitor suppressing IL-1β, IL-6, and TNF-α besides other proinflammatory cytokines [2] . Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study	./cache/cord-338968-b1gg2ha7.txt	./txt/cord-338968-b1gg2ha7.txt